Cipla gets USFDA nod for anti-viral eye infection drug for AIDS patients

Drug major Cipla Monday said it has received final approval from the US health regulator for Valganciclovir tablets, used in the treatment of viral eye infection in AIDS patients.

Valganciclovir tablets are used in the treatment cytomegalovirus infection (serious viral eye infection of the retina) in AIDS patients and in prevention of cytomegalovirus (CMV) disease after organ transplant.

The approved products is a generic therapeutic equivalent version of Roche’s Valcyte.

Cipla has received approval for the product in the strength of 450 mg from the United States Food and Drug Administration (USFDA), the company said in a BSE filing.

Quoting IQVIA (IMS Health) data, Cipla said Valcyte and its generic equivalents had US sales of around USD 79 million for the 12-month period ending September 2018.

Shares of Cipla were trading 1.09 per cent higher at Rs 532.95 apiece on BSE.

  • Related Posts

    Piyush Goyal meets pharma industry leaders to discuss R&D, competitiveness boost

    New Delhi: Union Commerce and Industry Minister Piyush Goyal has discussed strategies to boost competitiveness and strengthen research and development activities with the business representatives of the pharmaceutical industry. “Had…

    Senores Pharma to Buy Two Teva ANDAs

    Mumbai, August 14, 2025 — Senores Pharmaceuticals will acquire two abbreviated new drug applications (ANDAs) from Teva Pharmaceuticals USA. The deal is Senores’ third US move in six months, underscoring…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Piyush Goyal meets pharma industry leaders to discuss R&D, competitiveness boost

    Piyush Goyal meets pharma industry leaders to discuss R&D, competitiveness boost

    Senores Pharma to Buy Two Teva ANDAs

    Senores Pharma to Buy Two Teva ANDAs

    Lab-grown rabies antibodies show promise as cheaper, safer alternative

    Lab-grown rabies antibodies show promise as cheaper, safer alternative

    Lilly launches Mounjaro KwikPen in India

    Lilly launches Mounjaro KwikPen in India